Patient-reported outcomes enhance understanding of the impact of pazopanib in soft tissue sarcoma
- PMID: 26033391
- DOI: 10.1002/cncr.29429
Patient-reported outcomes enhance understanding of the impact of pazopanib in soft tissue sarcoma
Comment on
-
Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).Cancer. 2015 Sep 1;121(17):2933-41. doi: 10.1002/cncr.29426. Epub 2015 May 29. Cancer. 2015. PMID: 26033286 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
